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a b s t r a c t
Human papillomavirus type 16 is commonly implicated in HPV-related cancers. However, only a small
number of infected individuals progress to this stage. Epidemiological evidence demonstrated that
oncogenic risk is population-speciﬁc and variations within the viral oncogene, E6, have been suggested
to play a role in these ﬁndings. Of focus in this study is the European-T350G variant, which is
characterized by an L4V amino acid substitution at residue 83 of the prototype E6 protein. To elucidate
the functional effects of this polymorphism, we followed keratinocytes transduced with E-T350G E6 for
over 60 passages and compared them to keratinocytes transduced, in parallel, with prototype or Asian-
American (Q14H/L83V/H78Y) E6. We found that although E-T350G E6 immortalized transduced
keratinocytes in the absence of E7, these cells were not fully transformed. We also found that E-
T350G down-regulated E-cadherin compared to the other variants, providing a possible link between its
population-based oncogenicity and host genetic variations.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Human papillomavirus 16 (HPV16), belonging to species Alpha-
papillomavirus-9, is the most common HPV type detected in early
and malignant lesions of the cervix worldwide (Clifford et al., 2005;
Crow, 2012) as well as in HPV-related cancers of the head and neck,
the number of which has been notably increasing in recent years
(Garbuglia, 2014). It can be divided into four variant lineages: A
(which includes the European prototype sublineages A1/A2/A3 and
the Asian sublineage A4), B (which includes the African-1 sub-
lineages B1/B2), C (African-2) and D (which includes the North
American sublineage D1 and the Asian-American sublineages D2/
D3) characterized by single nucleotide polymorphisms (SNPs) found
throughout the whole viral genome which have evolved through
the process of lineage ﬁxation (Chen et al., 2005; Burk et al., 2013).
The original HPV16 reference sequence (GenBank accession no.
K02718.1) was ﬁrst published in 1985 (Seedorf et al., 1985; Kennedy
et al., 1991). Subsequently, during the 1990s, Yamada et al. (1997)
began the mapping of HPV16 variants in samples obtained world-
wide and suggested that particular variants may be associated with
the grade of cervical disease (Wheeler et al., 1997). However, we
now know these associations are more complex, differing both
ethnically and geographically (Xi et al., 2007; Cornet et al., 2013).
Together with E7, the viral E6 oncoprotein plays a main role in
immortalizing and malignantly transforming HPV16-infected cells
(reviewed in Vande Pol and Klingelhutz (2013)). Accordingly, in an
effort to explain why only a small percentage of individuals proceed
to develop high-grade lesions and cancer, there has been a particular
focus on studying SNPs of the E6 gene. Cross-sectional studies
completed by our group in the late 1990s analyzed the E6 SNPs of
HPV16-positive Swedish women diagnosed with various stages of
cervical disease (Zehbe et al., 1998a, 1998b, 2001a, 2001b). We found
European prototype (EP) E6 to be over-represented in low-grade
lesions whereas European-T350G (E-T350G) E6 (EP E6 with a T350G
polymorphism which corresponds to an amino acid change of L83V)
was signiﬁcantly associated with high-grade lesions and invasive
cervical cancer. In a retrospective cohort study of Caucasian French
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women, we also found that E-T350G E6 conferred a two times higher
risk for both viral persistence and progression to high-grade lesions
than EP E6 (Grodzki et al., 2006). Conversely, in other European
populations within Germany, Denmark, Italy and the Czech Republic,
either no association or an increased risk associated with EP E6 was
found (Nindl et al., 1999; Gheit et al., 2011; Zehbe et al., 1998b,
2001a). Recently, the International Agency for Research on Cancer
(IARC) HPV Variant Study Group examined 1121 HPV16þ cervical
cancer cases and 400 HPV16þ controls worldwide (Cornet et al.,
2013). They found E-T350G E6 to be associated with an increased risk
of developing cervical cancer in Central and South America but not in
Europe or Central Asia. However, it is important to note that only
samples from a limited number of countries in each region were
included in this study, while data from others, such as China and
Japan, were lacking. American and Italian studies investigating HPV-
related head and neck cancers have also noted the presence of this
E6 variant in a large proportion of their HPV16þ samples (Gillison
et al., 2000; Boscolo-Rizzo et al., 2009). Chen et al. (2005) have
determined that, evolutionarily, codon 83 of the HPV16 E6 gene is
under diversifying selective pressure. When considered together
with the conﬂicting epidemiological data evaluating the risk asso-
ciated with E-T350G E6, this supports the concept that host genetic
factors or corresponding SNPs in other viral genes may work together
with the biological activity of E6 itself to determine cervical lesion
progression (Tsakogiannis et al., 2013; Cornet et al., 2013).
Indeed, work by us and others have begun elucidating the
functional and mechanistic characteristics of the E-T350G E6 protein,
demonstrating its unique oncogenic potential. Multiple groups have
conﬁrmed that E-T350G E6 is not more efﬁcient at degrading p53
(Lichtig et al., 2006; Asadurian et al., 2007; Zehbe et al., 2009; Sichero
et al., 2012; Hang et al., 2014). However, E-T350G E6 was associated
with increased binding to calcium-binding protein E6BP (Lichtig et al.,
2006) as well as resistance to calcium/serum-induced differentiation
(Asadurian et al., 2007). In addition, three-dimensional rafts of Near-
diploid Immortalized Keratinocytes (NIKS) (Allen-Hoffmann et al.,
2000) transduced with E-T350G E6 demonstrated a greater tendency
towards a dysplastic phenotype than EP E6, as indicated by coexpres-
sion of both cytokeratins K5 and K10 in suprabasal cells (Zehbe et al.,
2009). Chakrabarti et al. (2004) found E-T350G E6 enhanced MAPK
signaling and cooperation with Notch1 signaling in transfected HaCat
cells. This ﬁnding was corroborated by a study which followed
primary human foreskin keratinocytes (PHFKs) transduced with E-
T350G E6 plus E7 over 30 passages and found elevated MAP2K1
mRNA expression (Sichero et al., 2012).
In a relevant study recently completed by our group (Niccoli et al.,
2012), we were able to show for the ﬁrst time that E6 alone, in the
absence of E7, is sufﬁcient for the immortalization and transformation
of keratinocytes. PHFKs retrovirally transduced with the EP or the
Asian-American (AA) E6 variant (non-synonymous SNPs G145T/C335T/
T350G which correspond to amino acid changes of Q14H/H78Y/L83V)
were followed in two donors for up to 65 passages (Niccoli et al., 2012).
We found that, although AA E6 degraded p53 and increased hTERT
expression similarly to EP E6, AA had an enhanced ability to promote
cellular immortalization, malignant transformation and migration.
These data help elucidate the E6-speciﬁc cellular mechanisms under-
lying AA's higher risk for high-grade cervical intraepithelial neoplasias
(CIN2/3) and cervical cancer (Xi et al., 1997, 2007; Villa et al., 2000;
Berumen et al., 2001). However, to date, no similar long-term study
characterizing the in vitro functionality and oncogenic potential of E-
T350G E6 in the absence of E7 has been performed. Therefore, here, we
followed PHFKs transduced with E-T350G E6 for over 60 passages to
elucidate their immortalizing and transforming ability. These results
were compared and contrasted to PHFKs transduced, in parallel, with
AA or EP E6, as described in our previously published ﬁndings (Niccoli
et al., 2012), with the goal of discerning functional information which
may provide useful insight into epidemiological ﬁndings. Given that E-
T350G contains one of the three non-synonymous SNPs found in the
AA E6 protein, it was hypothesized that its functional abilities would lie
in between those of EP and AA E6.
Results
Relative E6 expression was similar between the variants at the
protein level
To conﬁrm the success of our retroviral transductions and
provide a baseline for the downstream functional assays performed
Fig. 1. Relative expression of the E-T350G, European prototype (EP), and Asian-American (AA) E6 variants. (A) Expression of E6 mRNA was measured at passages 6, 16, 30 and 60
using RT-qPCR then calculated relative to the reference gene HPRT1 using the modiﬁed Livak method (2ΔCt). Statistical analyses were performed using a two-way ANOVA
followed by TukeyHSD contrasts post-hoc (n¼3 for each, except E-T350G P16: n¼2). (B) A representative Western blot for HA-E6 and the corresponding housekeeping
protein actin, with PHFKs as an HA-E6 negative control. (C) E6 protein expression was measured in high passage cells. Densitometry data were normalized to the
housekeeping protein actin and calculated relative to EP expression (represented by the dotted line at a ratio of 1). Statistical analyses were performed using a one-way
ANOVA (n¼3 for each). Data are presented as meansþSD. *denotes signiﬁcance.
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in this study, E6 expression was characterized for all three variants:
EP, E-T350G, and AA. E6 mRNA was measured at passages 6, 16, 30
and 60 using RT-qPCR and normalized to that of the reference gene
HPRT1 (Fig. 1A). E6 mRNA was detected in all three variants and,
overall, its levels varied between passages (Po0.001). EP E6 mRNA
expression was signiﬁcantly higher at P60 than it was at P6, P16 and
P30 (Po0.01 for all) and AA E6 mRNA expression was signiﬁcantly
higher at P30 than it was at P16 (Po0.01). We also found EP E6
mRNA expression was greater than that of E-T350G and AA at P60
(Po0.01 for both). However, there is not always a direct one-to-one
relationship between the amount of a transcript and the corre-
sponding amount of protein within a cell (Gry et al., 2009).
Accordingly, Western blots were then completed on high passage
cells to examine whether this difference between the variants was
substantiated at the protein level. Due to the lack of high afﬁnity,
commercially available HPV16 E6 antibodies (Jackson et al., 2013)
and the possibility that these antibodies may not have equal
afﬁnities to the variants, detection of an HA tag was used as a
proxy for E6 protein levels (Fig. 1B). HA-E6 densitometry data were
normalized to the housekeeping protein actin and calculated
relative to EP expression (Fig. 1C). Notably, we determined that E6
expression was not signiﬁcantly different between the variants
(P40.05) at the protein level. Therefore, this strengthens our ability
to attribute any unique oncogenic characteristics of the E-T350G
polymorphism to resulting differences in the functional or mechan-
istic abilities of the E6 protein.
E-T350G E6 enhanced cellular proliferation to a similar extent as AA
E6
As similarly demonstrated by our group for EP and AA E6 (Niccoli
et al., 2012), we found here that E-T350G E6 was also able to extend
the lifespan of retrovirally transduced keratinocytes in the absence of
other viral proteins (e.g., E7). We have previously reported that cells
transduced with AA E6 took signiﬁcantly fewer days to reach passage
65, had signiﬁcantly more population doublings and had signiﬁcantly
shorter population doubling times than cells transduced with EP E6
(Niccoli et al., 2012). Here, we examined these characteristics in cells
transduced with E-T350G E6. We found they took a total of 484 days
to grow between passages 6 and 65, whereas, cells transduced with
AA or EP E6 took a total of 495 and 662 days, respectively (Fig. 2A).
On average, both E-T350G E6 and AA E6 took signiﬁcantly fewer days
to passage than EP E6 (Po0.001 for both). Accordingly, EP E6 had
fewer average population doublings between each passage (Fig. 2B)
as well as a greater mean doubling time (108.57797.37 h) than E-
T350G E6 (67.02773.47 h) and AA E6 (58.28740.28 h) (Po0.01 for
all) (Fig. 2C). This demonstrated that E-T350G E6 was able to enhance
cellular proliferation to a similar extent as AA.
All E6 variants were able to immortalize transduced keratinocytes,
with both AA and E-T350G demonstrating an accelerated escape from
growth crisis compared to EP E6
Somatic cells, such as PHFKs, normally have a ﬁnite lifespan (as
reviewed in Blasco (2005)). One of the hallmarks of cancer is the
ability of cells to overcome this growth crisis and continue replicating
for an inﬁnite length of time—a phenomenon termed immortaliza-
tion. Interestingly, both E-T350G and AA E6 exhibited an earlier
growth crisis and escaped from it more quickly than EP E6; E-T350G
and AA E6 both demonstrated a crisis at P9, with E-T350G E6 taking
583 h and AA E6 334 h to double during this passage whereas EP E6
demonstrated a crisis at P19, taking 700 h to double (Fig. 2C).
Therefore, we next sought to characterize any variant-speciﬁc
inﬂuences on the cellular processes underlying this observation.
One of the most well-known functions of HPV16 E6 is its ability to
complex with E6AP and cause the ubiquitin-mediated degradation of
the p53 protein (Scheffner et al., 1993). This prevents host cells from
entering G1 cell cycle arrest following DNA damage, thus contribut-
ing to their continued growth in the absence of normal mitogenic
signals. Niccoli et al. (2012) have previously demonstrated that both
EP and AA E6 were equally able to overcome G1 arrest following DNA
damage induced by actinomycin D. Here, we calculated the G1:S ratio
(ratio41 implies growth arrest, ratioo1 implies DNA replication)
for cells treated with actinomycin D at passages 16, 31 and 62, using
ﬂow cytometry (Fig. 3A). Overall, the G1:S ratio decreased across
passages (Po0.001). While the G1:S ratio was only signiﬁcantly
lower at P62 than it was at P16 for EP E6 (Po0.05), it was
signiﬁcantly lower at P62 than it was at both P16 and P31 for E-
T350G E6 (Po0.001 for both). At P31, EP E6 had a signiﬁcantly lower
G1:S ratio than E-T350G E6 (Po0.05). However, by P62, E-T350G E6
displayed a greater ability to overcome G1 arrest than both EP and
AA E6 (Po0.05 for both). Western blotting demonstrated p53
protein was abolished for all three variants (Fig. 3B). Treatment with
actinomycin D yielded similar results (data not shown). Previous
studies completed by our group using NIKS retrovirally transduced in
a similar manner have conﬁrmed that E-T350G E6 is not more
efﬁcient at degrading p53 than EP and AA E6 (Zehbe et al., 2011),
thus eliminating this as an underlying cause for the differences
observed here.
Studies completed on normal human gingival keratinocytes trans-
duced with HPV16 E6 alone have shown that inactivation of p16INK4A
and restoration of telomere maintenance pathways are also required
for completion of the immortalization process (Tsutsui et al., 2002).
Accordingly, we detect p16INK4A expression in early passage cells (P6)
for all three variants (Fig. 3B). At P16 and above, p16INK4A is abolished
for all three variants and, interestingly, this is three passages prior to
the observation of a growth crisis in EP cells. In addition, E6 proteins of
high-risk Alphapapillomavirus types have been shown to upregulate
hTERT expression, the catalytic subunit of the enzyme telomerase
(Klingelhutz et al., 1996; Veldman et al., 2003; Gewin et al., 2004;
Katzenellenbogen et al., 2007). Accordingly, we measured hTERT
mRNA levels at passages 6, 16, 30 and 60 for all three variants using
RT-qPCR and normalized them to those of the reference HPRT1
(Fig. 3C). Overall, hTERT mRNA expression differed between passages
as well as variants (Po0.001 for both). E-T350G hTERT mRNA
expression signiﬁcantly increased with passage, being higher at P16,
P30 and P60 than P6 (Po0.001 for all) and higher at P30 than P16
(Po0.05). However, AA hTERT mRNA expression was higher only at
P30 than P6 (Po0.05) and EP hTERT mRNA expression did not
signiﬁcantly increase with passage. Notably, E-T350G had greater
hTERT mRNA levels than EP at P16, P30 and P60 (Po0.01 for all)
and than AA at P30 as well as P60 (Po0.001 for both). AA only had
greater hTERTmRNA expression than EP at P30 (Po0.05). When taken
together, these results demonstrated that both E-T350G and AA E6
upregulated hTERT mRNA expression more so than EP E6, which may
have facilitated an accelerated escape from their growth crises.
Interestingly, E-T350G E6 sustained these levels throughout higher
passages more so than AA E6.
Cells transduced with E-T350G E6 demonstrated characteristics of a
malignant phenotype but were not transformed in vitro
Following immortalization, we have found in previous studies
that both AA E6 and EP E6 were able to induce characteristics of a
malignant phenotype, but that only AA E6 was able to transform
cells in vitro in the absence of E7 (Niccoli et al., 2012). First, we
examined the ability of E6 transduced cells to avoid detachment-
induced cell death, otherwise known as anoikis, following growth
in semi-solid medium for 24 h. The percent of early apoptotic cells
(stained positive for Annexin V but not propidium iodide) as well
as the percent of late apoptotic cells (stained positive for both
Annexin V and propidium iodide, due to a loss of membrane
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integrity) were quantiﬁed at passages 16, 30 and 61 using ﬂow
cytometry (Fig. 4A and B). Overall, the percent of early apoptotic
cells differed between passages as well as between variants
(Po0.001 for both). EP E6 had less early apoptotic cells at P30
than both P16 and P61 (Po0.05 for both) and E-T350G E6 had less
at P30 than P16 (Po0.01). However, at P61, both E-T350G and AA
had signiﬁcantly fewer early apoptotic cells than EP (Po0.001 for
both). When analyzed similarly, we found the percent of late
apoptotic cells decreased as passage increased. This was demon-
strated by EP and AA having signiﬁcantly less positively stained
cells at P30 and P61 than at P16 (Po0.05 for all). E-T350G E6
maintained a relatively lower amount of late apoptotic cells than
AA and EP E6 across all passages, reaching signiﬁcance at both P16
and P30 (Po0.001 for all).
We then determined the ability of high passage cells (P65)
transduced with E-T350G E6 to form colonies when grown on
semi-soft agar in an in vitro transformation assay, as described
previously by us (Richard et al., 2010). Following colony growth,
cells were extracted from the agar and an MTT assay used to
quantitatively determine viability (Fig. 4C). However, despite E-
T350G E6's enhanced ability to prevent anoikis, only AA formed
viable colonies (Po0.001).
E-T350G E6 signiﬁcantly down-regulated E-cadherin expression at
the protein level
Down-regulated E-cadherin by transforming keratinocytes decreases
cell–cell adhesion, facilitating an epithelial-to-mesenchymal transition
(EMT) and invasion through the basement membrane into surrounding
tissues. In addition, an E6-dependent decrease in E-cadherin has also
been associated with the ability of infected keratinocytes to escape host
immune surveillance due to depletion of intraepithelial Langerhans cells
(Matthews et al., 2003). Thus, Western blots were also performed on
high passage cells to assess whether the variants differentially affected
E-cadherin protein levels (Fig. 5A). E-cadherin densitometry data were
normalized to the housekeeping protein actin and calculated relative to
EP expression (Fig. 5B). Our results showed that cells transducedwith E-
T350G E6 had signiﬁcantly less E-cadherin expression than cells
transduced with EP or AA E6 (Po0.01 for both). Surprisingly, AA E6
did not signiﬁcantly reduce E-cadherin expression compared to EP E6,
further demonstrating the unique capabilities of E-T350G E6.
Discussion
In this study, we examined the oncogenic capabilities of the E-
T350G E6 protein in retrovirally transduced PHFKs. Ours is the ﬁrst
such investigation to characterize the immortalization and malig-
nant transformation potential of this variant alone, in the absence of
E7's complementary effects, over an extended number of passages.
The ability for particular E6 variants to achieve this challenges the
conventional understanding that both E6 and E7 are required (as
described in Niccoli et al. (2012)). In HPV-induced carcinogenesis,
E7 degrades pRb, subsequently releasing the transcription factor
E2F and promoting cellular proliferation (Pagano et al., 1992).
However, previous studies have shown that E6 can also activate
E2F-responsive genes, although by a different mechanism than that
of E7 (Malanchi et al., 2004; Shai et al., 2007). E6 increases CDK2
Fig. 2. Cellular proliferation of keratinocytes transduced with E-T350G, European prototype (EP), or Asian-American (AA) E6 from passages 6–65. (A) Cumulative number of days to
reach each passage. (B) Cumulative number of population doublings at each passage. (C) Average doubling time in hours as calculated using the formula 3.32(log Nt log
No)¼tf, where Nt is the number of cells counted and No is the number of cells plated, t is the time in days between passages, and f is the growth rate constant. Statistical
analyses were performed using a one-way ANOVA followed by TukeyHSD contrasts post-hoc (n¼60 for each). Growth crises are identiﬁed by arrows. *denotes signiﬁcance.
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activity and decreases p21WAF1/CIP1 protein expression, resulting in
pRb hyperphosphorylation (Malanchi et al., 2004). For successful
passage through growth crisis, p16INK4A, a CDK4/6 inhibitor, must be
inactivated by methylation or possibly by selection of keratinocyte
populations harboring mutations (Rheinwald et al., 2002). In addi-
tion, elongation of telomeres, either by activation of hTERT or ALT
mechanisms, must be initiated (Stewart et al., 2002). Although we
initially see p16INK4A expression in low passage cells, the fact that it
is absent prior to EP's growth crisis together with the observed
increase in hTERT mRNA by P16 suggests that the observed growth
crises for the variants were more likely to be caused by telomere
shortening than pRb/p16INK4A induced senescence. Future studies
are needed to conﬁrm telomere shortening and to examine possible
variant speciﬁc differences in crisis escape.
E-T350G E6 demonstrated a better ability to enhance hTERT
expression and maintain it at higher levels for a greater number of
passages than both EP and AA E6. In the literature, multiple mechan-
isms have been implicated in the ability of E6 to increase hTERT. For
example, it has been suggested that E6 co-localizes with c-myc at E-
box elements of the hTERT promoter (Veldman et al., 2003). In
addition, it has also been shown that the E6/E6AP complex targets
NFX1-91, a repressor of the hTERT promoter, for ubiquitin-mediated
proteasomal degradation (Gewin et al., 2004) and interacts with
NFX1-123, recruiting it directly to the hTERT promoter or facilitating
its interaction with cytoplasmic poly(A) binding proteins (PABPCs) to
increase hTERT protein expression (Katzenellenbogen et al., 2007).
Therefore, it is possible that the E6 variants may differentially exploit
these mechanisms to modulate hTERT expression. However, despite
E-T350G's enhanced ability to upregulate hTERT, its crisis and popula-
tion doubling characteristics were on par with those of AA E6. Elevated
hTERT expression is not the sole indicator for enhanced immortaliza-
tion potential, as additional increases in hTERT expression may be
dispensable (McMurray and McCance, 2004).
Overall, we have shown that E-T350G E6 in the absence of E7
can functionally promote the immortalization and acquisition of a
malignant phenotype in transduced cells. However, these changes
fall short of causing in vitro transformation, such as seen with AA
E6 alone. We previously demonstrated that PHFKs transduced
with AA E6 plus E7 produced a signiﬁcantly higher number of
viable colonies than EP E6 plus E7 (Richard et al., 2010). In
addition, a 2012 study by Sichero et al. which used a similar
in vitromodel demonstrated that, in the presence of E7, both AA E6
and E-T350G E6 could promote the formation of more colonies
than EP E6, when the cells were grown in semi-soft agar. This
suggests that, although E-T350G E6 may promote immortalization
and the development of certain aspects of a malignant phenotype
with a similar efﬁciency to AA E6, it requires the complementary
functional effects of E7 or additional host-dependent factors to
cause complete cellular transformation.
Fig. 3. Immortalization indicators of keratinocytes transduced with E-T350G, European prototype (EP), or Asian-American (AA) E6. (A) G1:S ratio was measured at passages 16, 31
and 62 using ﬂow cytometry, following treatment of the cells with actinomycin D (ActD) to induce DNA damage. A G1:S ratio41 implies growth arrest whereas a ratio o1
implies DNA replication is occurring (indicated by the dotted line at a ratio of 1). Statistical analyses were performed using a two-way ANOVA followed by TukeyHSD
contrasts post-hoc (n¼3 for each). (B) Western blots at passage 6, 16, 30, and 65 for p53, p16INK4A, and actin. PHFKs were used as a p53 positive control, whereas PHFKs
transduced with E7 was used as a p16 positive control. (C) Expression of hTERT mRNA was measured at passages 6, 16, 30 and 60 using RT-qPCR then calculated relative to
the reference gene HPRT1 using the modiﬁed Livak method (2ΔCt). Statistical analyses were performed using a two-way ANOVA followed by TukeyHSD contrasts post-hoc
(n¼3 for each, except E-T350G P16: n¼2). Data are presented as meansþSD. *denotes signiﬁcance.
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Another interesting aspect of E-T350G E6 is its unique ability to
down-regulate E-cadherin. In vivo, a subsequent depletion of
intraepithelial Langerhans cells could lead to limited antigen pre-
senting opportunities, ultimately repressing a cell-mediated
immune response and permitting viral persistence (Matthews
et al., 2003). When further coupled with host-dependent immuno-
logical variations, oncogenic risk associated with E-T350G may be
increased. This hypothesis is supported by previous suggestions
that there is selective pressure driven by the host immune system
on residue 83 of E6, coincident with host HLA variations (Chen et al.,
2005). In correlation studies between HPV16 E6 variants, HLA and
cervical cancer risk, we and others found an association between E-
T350G E6 and HLA II haplotype DRn04-DQn03 (Zehbe et al., 2001b;
Beskow et al., 2005). Our group has also found that E-T350G E6
conferred a 4–5 fold increased risk of developing invasive cervical
cancer compared to controls when HLA I haplotypes Bn44, 51 and
57 were present (Zehbe et al., 2003). Functional validation of these
correlations may aid in explaining the variability observed in
population speciﬁc risk studies (de Araujo Souza et al., 2009).
Materials and methods
Cell culture
Mammalian cells were cultured as previously described (Richard
et al., 2010; Niccoli et al., 2012). Brieﬂy, cells were maintained in a 5%
CO2, 37 1C humidiﬁed incubator with PHFKs cultured in serum-free
Keratinocyte Growth Medium (KGM; Cell Applications Inc., San Diego,
CA, USA) and Phoenix cells (gift from Dr. Garry P. Nolan, Stanford
University, CA, USA) cultured in Dulbecco's Modiﬁed Eagle Medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and 1%
antibiotics/antimycotics. PHFKs were passaged at 70–80% conﬂuence
using trypsin-EDTA to detach the cells followed by inactivation with
trypsin neutralizing solution (Cell Applications Inc.). At each passage,
cells were counted with either a Coulter counter or TC10 automated
cell counter (Bio-Rad, Mississauga, ON, Canada). For the long-term
propagation of PHFKs, 125,000 cells were re-seeded each passage.
Retroviral transductions
Variant E6 genes were stably transduced into PHFKs using
retroviral-containing supernatant from Phoenix cells, as previously
described (Richard et al., 2010; Niccoli et al., 2012). Brieﬂy, pLXSN
plasmids contained E6 variant genes and encoded a hemagglutinin
(HA) tag for downstream detection by Western blot. Plasmids
were ampliﬁed in Escherichia coli, puriﬁed, and transfected by
calcium phosphate precipitation into Phoenix cells. Viral super-
natant from transfected Phoenix cells was added, along with
polybrene, to PHFKs. Infected PHFKs were selected by 100 mg/mL
gentamicin (G418; Roche, Laval, QC, Canada), ensuring that only
stable transduced populations remained.
RT-qPCR
Relative quantiﬁcation of gene expression was acquired using
RT-qPCR, as previously described (Richard et al., 2010; Niccoli
et al., 2012). First, cell pellets were collected, washed with PBS, and
stored at 80 1C. Total RNA was extracted using the RNAqueous
Total RNA Isolation Kit (Life Technologies, Burlington, ON, Canada).
Fig. 4. Malignant characteristics and transformation of keratinocytes transduced with E-T350G, European prototype (EP), or Asian-American (AA) E6. (A) and (B) An Annexin
V-FITC ﬂow cytometry assay was used to determine the percent of early and late apoptotic cells at passages 16, 30 and 61, following induction of anoikis by growth in semi-
solid medium. Statistical analyses were performed using a two-way ANOVA followed by TukeyHSD contrasts post-hoc (n¼3 for each). (C) An MTT assay (read at an
absorbance of 570 nm) was used to quantify the viable colonies formed by high passage cells which were grown on semi-soft agar in an in vitro transformation assay.
Statistical analyses were performed using a two-way ANOVA followed by TukeyHSD contrasts post-hoc (n¼5 for each). Data are presented as meansþSD. *denotes
signiﬁcance.
M. Togtema et al. / Virology 485 (2015) 274–282 279
The quantity and integrity of RNA were assessed using the
Experion Automated Electrophoresis system with a StdSens chip
(Bio-Rad), while purity was conﬁrmed spectrophotometrically.
RNA was reverse transcribed into cDNA using the High Capacity
cDNA Archive Kit (Life Technologies). RT-qPCR reactions consisted
of 150 ng of cDNA, 45 mL of TaqMan Gene Expression Master Mix
(Life Technologies), 4.5 mL of TaqMan Gene Expression Assay
hydrolysis probes (HPRT1, HPV16 E6, and hTERT), and nuclease-
free water for a ﬁnal volume of 90 mL. Triplicate reaction volumes
of 25 mL for each sample were loaded into transparent 96-well
plates and analyzed using a 7500 ABI real-time thermocycler.
Hypoxanthine phosphoribosyltransferase 1 (HPRT1) was chosen as
a stable reference gene based on previous experiments (DeCarlo
et al., 2008). Relative expression was calculated by the modiﬁed
Livak method: 2ΔCt (Livak and Schmittgen, 2001).
Flow cytometry
Cell cycle (G1:S ratios) and anoikis were assessed using a
FACSCalibur ﬂow cytometer (BD, Mississauga, ON, Canada), as
previously described (Richard et al., 2010; Niccoli et al., 2012).
Brieﬂy, cell cycle analysis was performed on cells treated with
0.5 nM actinomycin D for 24 h to induce DNA damage or DMSO as
a negative control, followed by ﬁxation and incubation with
propidium iodide (5 mg/mL). To quantify early and late apoptotic
cells, anoikis was induced by growing cells in semi-solid media for
24 h followed by use of an Annexin V-FITC assay.
In vitro transformation assay
The ability for E6-variant transduced cells to form viable colonies
in semi-soft agar was assessed using the CytoSelect 96-well Cell
Transformation Kit (Cell BioLabs, San Diego, CA, USA) followed by
an MTT assay, both of which were described previously (Richard
et al., 2010; Niccoli et al., 2012). Brieﬂy, late passage (passage 65)
PHFKs containing the E6 variants (EP, E-T350G, AA) were seeded in
triplicate into the 96-well plate (5000 cells/well). Biological nega-
tive and positive controls were also included (passage 3 parental
PHFKs and HeLa cells, respectively). The presence of viable colonies
was assessed after 10 days following agar solubilization and cell
lysis. Cell viability was assessed with an MTT assay and absorbance
measured at 570 nm using a spectrophotometer.
Protein extraction, SDS-PAGE, and Western blot
Protein-level expression of HA-E6, E-cadherin, p53, and p16INK4A
was assessed by Western blot. For HA-E6 and E-cadherin, protein was
extracted as whole cell lysates from high passage cells (passage 70þ)
which were collected by scraping, as trypsinization cleaves transmem-
brane E-cadherin. Cells used for detecting p53 and p16INK4A were
collected at passage 6, 16, 30, and 65 by trypsinization. Lysis was
performed in chilled RIPA buffer (50 mM Tris–HCl pH 7.5, 150 mM
NaCl, 0.1% SDS, 1% sodium deoxycholate, 1% Triton X-100, 5 mM EDTA,
10 mM NaF) with the fresh addition of 10 mM PMSF and a 1:100
dilution of Protease Inhibitor Cocktail (Sigma, Oakville, ON, Canada) for
20 min on ice. Protein concentration quantiﬁcation was performed
using a Detergent Compatible Protein Assay (Bio-Rad), followed by the
loading of denatured samples onto pre-cast 4–20% gradient gels (Bio-
Rad), with 30–50 mg of protein in each well. Gels were run at 120 V for
70 min and then transferred to PVDF membranes for 1 h at 100 V.
Membranes were blocked in 5% non-fat dry milk in TBS-T (0.05%),
followed by overnight primary antibody incubation at 4 1C. The
following primary antibodies and dilutions were used: monoclonal
mouse anti-E-cadherin (DAKO, Burlington, ON, Canada; clone NCH-38,
diluted 1:1000 in blocking buffer), monoclonal mouse anti-HA
(Abcam, Toronto, ON, Canada; clone HA.C5, diluted 1:500), mono-
clonal mouse anti-p53 (DAKO, Burlington, ON, Canada; clone DO-7,
diluted 1:1000), monoclonal mouse anti-p16INK4A (Santa Cruz, Dallas,
TX, USA; clone JC8, diluted 1:200), and as a loading control, polyclonal
goat anti-actin (Santa Cruz, Dallas, TX, USA; clone I-19, diluted 1:1000).
Washes were performed with TBS-T (0.05%), followed by incubation
with HRP-conjugated secondary antibodies at room temperature: goat
anti-mouse for E-cadherin, HA, p53 and p16 (Jackson Immunore-
search, West Grove, PA, USA; diluted 1:2000 in blocking buffer) and
donkey anti-goat for actin (Jackson Immunoresearch, diluted 1:2000).
Western Lightning Plus-ECL (PerkinElmer Inc., Waltham, MA, USA)
and a BioSpectrum 410 Imaging System (UVP, Upland, CA, USA) were
used for detection: E-cadherin (120 kDa), p53 (53 kDa), actin (42 kDa),
HA (18 kDa), and p16INK4A (16 kDa). Relative protein expression was
measured by densitometry using VisionWorks software with actin
used as a reference loading control for each sample.
Statistics
All statistical analyses were performed using the statistical
programming language R (version 3.1.0; R Core Team, Vienna: R
Foundation for Statistical Computing [http://www.R-project.org]).
The signiﬁcance level, alpha, was set to 0.05 for all analyses. One or
two-way analysis of variance (ANOVA) was used as a global test of
signiﬁcance followed by post-hoc analysis with the TukeyHSD test
to determine which speciﬁc pair-wise comparisons were signiﬁ-
cantly different. Data are presented as meansþstandard deviation.
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